June 24, 2022
Indivior, Aquestive and Dr. Reddy's Laboratories have ended their yearslong litigation battle over generic versions of the opioid addiction treatment Suboxone, with the Indian drugmaker on Friday saying it will receive $72 million by April 2024.
September 19, 2019
Goodwin-backed Dr. Reddy's Laboratories has asked a Delaware federal judge for more than $3 million in attorney fees after beating Indivior's patent infringement suit over the opioid addiction treatment Suboxone, saying the company took a hopeless case to trial and undermined the litigation by filing a similar suit in New Jersey.
September 01, 2017
Indivior PLC said Friday a Delaware federal judge found a product developed by Dr. Reddy's Laboratories does not infringe three of its patents for Suboxone, clearing the way for a generic version of the opiate addiction treatment, which generates 80 percent of Indivior's revenue.